The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

被引：3

作者：

Cha, Danielle S. ^{[1
,2
,3
,4
,5
]}

Kleine, Nicholas ^{[4
,6
]}

Teopiz, Kayla M. ^{[4
,6
]}

Di Vincenzo, Joshua D. ^{[3
,4
]}

Ho, Roger ^{[7
,8
]}

Galibert, Stephanie L. ^{[9
]}

Samra, Amrita ^{[5
]}

Zilm, Samuel P. M. ^{[5
]}

Cha, Rebekah H. ^{[10
]}

d'Andrea, Giacomo ^{[8
]}

Gill, Hartej ^{[3
,11
]}

Ceban, Felicia ^{[3
,4
,10
]}

Meshkat, Shakila ^{[3
]}

Wong, Sabrina ^{[3
,4
]}

Le, Gia Han ^{[3
,11
]}

Kwan, Angela T. H. ^{[3
,11
]}

Rosenblat, Joshua D. ^{[3
,4
,12
]}

Rhee, Taeho Greg ^{[13
,14
]}

Mansur, Rodrigo B. ^{[3
,4
]}

Mcintyre, Roger S. ^{[15
,16
,17
,18
,19
,20
,21
,22
,23
]}

机构：

[1] Royal Brisbane & Womens Hosp, Mental Hlth Serv, Brisbane, Qld, Australia

[2] Univ Queensland, Sch Clin Med, Royal Brisbane Clin Unit, Brisbane, Qld, Australia

[3] Brain & Cognit Fdn, Toronto, ON, Canada

[4] Univ Hlth Network, Toronto Western Hosp, Mood Disorders Psychopharmacol Dept, Toronto, ON, Canada

[5] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Brisbane, Qld, Australia

[6] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada

[7] Natl Univ Singapore, Inst Hlth Innovat & Technol iHealthtech, Singapore, Singapore

[8] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy

[9] Logan Hosp, Dept Obstet & Gynaecol, Logan, Qld, Australia

[10] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada

[11] Univ Toronto, Inst Med Sci, Toronto, ON, Canada

[12] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[13] Yale Sch Med, Dept Psychiat, New Haven, CT USA

[14] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA

[15] Univ Toronto, Dept Psychiat & Pharmacol, Toronto, ON, Canada

[16] Brain & Cognit Discovery Fdn BCDF, Toronto, ON, Canada

[17] Depress & Bipolar Support Alliance DBSA Board Dire, Board Chair, Chicago, IL USA

[18] Guangzhou Med Univ, Guangzhou, Peoples R China

[19] Korea Univ, Coll Med, Seoul, South Korea

[20] Univ Philippines, Coll Med, Manila, Philippines

[21] SUNY Upstate Med Univ, State Univ New York, Syracuse, NY USA

[22] Univ Calif Riverside, Sch Med, Dept Psychiat & Neurosci, Riverside, CA USA

[23] Univ Toronto, 77 Bloor St West,6th Floor Suite 617, Toronto, ON M5S 1M2, Canada

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 01期

基金：

加拿大健康研究院; 中国国家自然科学基金;

关键词：

Zuranolone; SAGE217; depression; postpartum/postpartum depression; rapid-acting; neuroactive steroid; GABA(A); positive allosteric modulator; COGNITIVE FUNCTION; ALLOSTERIC MODULATORS; MENTAL-DISORDERS; CLINICAL-TRIAL; IMPACT; HARM; ALPHAXALONE; OUTPATIENTS; IMPAIRMENT; LIKELIHOOD;

D O I：

10.1080/14656566.2023.2298340

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners. Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABA(A) receptors, is an attractive alternative as a rapid-acting antidepressant treatment.Areas covered: This article reviews zuranolone (SAGE217), focusing on available clinical studies in individuals with PPD and MDD. This paper adds to the extant literature by presenting the efficacy data as Number Needed to Treat (NNT) to facilitate indirect comparisons with other antidepressants.Expert opinion: Zuranolone is a novel rapid-acting (i.e. two week course) oral antidepressant for the treatment of adults with PPD with ongoing clinical trials evaluating its efficacy in adults with MDD. Zuranolone is well tolerated with no significant safety concerns in any clinical trials completed to date. Zuranolone will be scheduled by the Drug Enforcement Agency (DEA).

引用

页码：5 / 14

页数：10

共 50 条

[21] Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
Clayton, A.
Cutler, A. J.
Deligiannidis, K. M.
Lasser, R.
Sankoh, J.
Doherty, J.
Kotecha, M.
EUROPEAN PSYCHIATRY, 2022, 65 : S97 - S98
[22] Number needed to treat (NNT)-challenges in interpretation. A literature review.
Ghosh, AK
Ghosh, K
JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 : 184 - 184
[23] Cost Needed to Treat (CNT) and Number Needed to Treat (NNT) analysis of drugs for treatment of heart failure in India
Thannikkal, A.
George, V.
Mullavelil, K.
Koshy, C.
Venugopal, K.
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2020, 19 (1_SUPPL) : S30 - S31
[24] Cost Needed to Treat (CNT) and Number Needed to Treat (NNT) analysis of drugs for treatment of heart failure in India
Mullavelil, K.
George, V
Thannikkal, A.
Aravindakshan, R.
John, D.
Koshy, C.
Venugopal, K.
EUROPEAN HEART JOURNAL, 2020, 41 : 3539 - 3539
[25] Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome, L.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (09) : 978 - 997
[26] Applying number-needed-to-treat (NNT) analysis to ophthalmic clinical trials
Varner, Paul
OPTOMETRY AND VISION SCIENCE, 2006, 83 (12) : 919 - 930
[27] Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Citrome, Leslie
Goldberg, Joseph F.
Portland, Kimberly Blanchard
JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (02) : 409 - 417
[28] Heterogeneity of major depressive disorder versus postpartum depression
Kasper, S.
EUROPEAN PSYCHIATRY, 2020, 63 : S605 - S606
[29] Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
Clayton, A. H.
Deligiannidis, K. M.
Ramos-Quiroga, J. A.
Lasser, R.
Sankoh, A. J.
Leclair, B.
Kotecha, M.
Doherty, J.
EUROPEAN PSYCHIATRY, 2023, 66 : S93 - S94
[30] A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
Wong, Sabrina
Kwan, Angela T. H.
Teopiz, Kayla M.
Le, Gia Han
Meshkat, Shakila
Ho, Roger
d'Andrea, Giacomo
Cao, Bing
Di Vincenzo, Joshua D.
Rosenblat, Joshua D.
McIntyre, Roger S.
JOURNAL OF AFFECTIVE DISORDERS, 2024, 350 : 698 - 705

← 1 2 3 4 5 →